SMN-independent approaches for spinal muscular atrophy

Mechanisms and SMN-Independent Therapies for Spinal Muscular Atrophy

NIH-funded research Columbia University Health Sciences · NIH-11307153

This project looks for new treatments for people with spinal muscular atrophy that work without relying only on restoring the SMN protein.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionColumbia University Health Sciences NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-11307153 on NIH RePORTER

What this research studies

This project studies why low SMN protein harms the nerves and muscles that control movement and tests therapies that do not depend on boosting SMN. Researchers use laboratory models, molecular studies, and gene-delivery tools such as AAV vectors to target other pathways that keep motor neurons and muscle healthy. The team aims to find treatments that could protect or restore function even in patients who do not fully respond to current SMN-focused drugs. Promising leads would be used to design future human studies and clinical trials.

Who could benefit from this research

Good fit: People with spinal muscular atrophy—especially infants, young children, or patients who have not fully responded to SMN-targeting therapies—would be the main focus for eventual clinical testing.

Not a fit: Patients with neurological conditions unrelated to SMA or those with very advanced, irreversible nerve and muscle damage are unlikely to benefit from the therapies under study.

Why it matters

Potential benefit: Could produce new treatments that help people with SMA, including those who gain limited benefit from current SMN-centered therapies.

How similar studies have performed: SMN-replacement therapies like Spinraza and AAV-based gene therapy have benefited many patients, but SMN-independent strategies are newer and less proven.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.